LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking presentations showcasing the results of a Phase 2b dose finding trial evaluating the efficacy and safety of ...
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback